Slavisa Ninkovic

St Vincent's Hospital Melbourne
Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Journal: Blood advances

Published: November 18, 2025

Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.

Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.

Journal: Leukemia & lymphoma

Published: September 04, 2024

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 05, 2024

Real-world utility of cytogenetic testing in cases with 'suspected myelodysplastic neoplasm but insufficient morphological features for diagnosis': a Victorian Cancer Cytogenetics Service experience.

Real-world utility of cytogenetic testing in cases with 'suspected myelodysplastic neoplasm but insufficient morphological features for diagnosis': a Victorian Cancer Cytogenetics Service experience.

Journal: Pathology

Published: May 21, 2024

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.

Journal: Haematologica

Published: September 19, 2023

The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).

The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).

Journal: EJHaem

Published: May 23, 2023

Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.

Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.

Journal: Haematologica

Published: May 18, 2023

Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.

Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.

Journal: British journal of haematology

Published: March 14, 2023

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview.

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview.

Journal: Cancers

Published: October 25, 2020

Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma.

Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma.

Journal: Expert review of hematology

Published: September 29, 2020

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.

Journal: British journal of haematology

Published: June 20, 2019

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Journal: British journal of haematology

Published: March 13, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026